To further delineate the role of PIM1, we tested PIM1 inhibition in vitro using pharmacologic and genetic approaches using PIM1mutant ABC‐DLBCL (OCI‐Ly3, TMD8, HBL1), GCB‐DLBCL (OCI‐Ly8) and a PIM1WT ABC‐DLBCL cell line (U‐2932) and GCB (DHL16) cell line (Table S3). The gene discussed is PIM1; the disease is diffuse large B-cell lymphoma.